Cresilon representatives will be available to talk about how TRAUMAGEL can be easily deployed to control bleeding in seconds across emergency response and military environments at the poster session ...
- Data from the ASCENT study of LIQ861 (YUTREPIA™) in PH-ILD patients highlights safety, tolerability, exploratory changes in six-minute walk distance, cardiac effort and quality of life - Case study ...
PharmaJet needle-free technology can improve DNA vaccine delivery 1 and has been successfully adopted into multiple cancer vaccine development programs. Partner study data shows how PharmaJet ...
Preclinical in vitro studies demonstrated >80% reduction in protease activity, including complete inhibition of TACE and collagenase — key factors in non-healing chronic wounds revyve® data featured ...
Clinical case series showed clinically meaningful reductions in wound size and pain, and improved tissue regranulation in chronic wound patients using revyve ® over 6–12 weeks Preclinical in vitro ...
Preclinical in vitro studies demonstrated >80% reduction in protease activity, including complete inhibition of TACE and collagenase - key factors in non-healing chronic wounds revyve ® data featured ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback